3-(2-吡嗪基)-3-氧代丙酸乙酯 | 62124-77-0

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(2-吡嗪基)-3-氧代丙酸乙酯
• 中文别名: 3-氧代-3-吡嗪-2-丙酸乙酯
• 英文名称: ethyl 3-oxo-3-(pyrazin-2-yl)propanoate
• 英文别名: ethyl β-oxo-2-pyrazinepropanoate；α-Pyrazincarbonyl-essigsaeure-ethylester；3-oxo-3-pyrazin-2-yl-propionic acid ethyl ester；ethyl 3-(pyrazin-2-yl)-3-oxopropionate；β-oxo-pyrazinepropanoic acid, ethyl ester；3-oxo-3-pyrazinyl-propionic acid ethyl ester；3-Oxo-3-pyrazinyl-propionsaeure-aethylester；ethyl 4-(2-pyrazinyl)-2,4-dioxobutanoate；ethyl β-oxopyrazinepropionate；Ethyl 3-(2-pyrazinyl)-3-oxopropanoate；ethyl 3-oxo-3-pyrazin-2-ylpropanoate
• CAS: 62124-77-0
• 化学式: C₉H₁₀N₂O₃
• 分子量: 194.19
• InChiKey: OPBDMDPBJKVMNL-UHFFFAOYSA-N

物化性质

• 熔点：
  61.0 to 65.0 °C
• 沸点：
  120°C/2mmHg(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P264,P280,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313
• 危险性描述：
  H315,H319
• 储存条件：
  室温且干燥环境中保存

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-oxo-3-pyrazin-2-yl-propionate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-oxo-3-pyrazin-2-yl-propionate
CAS number: 62124-77-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H10N2O3
Molecular weight: 194.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-(2-吡嗪基)-3-氧代丙酸乙酯是一种有机中间体，可由吡嗪-2-甲酸甲酯和甲酸乙酯或由丙二酸二乙酯和吡嗪-2-羰基氯反应得到。

制备

在装有机械搅拌器、冷凝器和滴液漏斗的三口烧瓶中，在110°C下，向搅拌的甲醇钠（25％的MeOH，27.54mL，72.4mmol，1当量）的90mL甲苯溶液中，于35-40分钟内逐滴加入吡嗪-2-甲酸甲酯（10g，72.4mmol，1当量）在115mL甲酸乙酯中的溶液。反应过程中形成黄色沉淀物。继续在110°C下搅拌3小时后，冷却并过滤黄色沉淀物，用少量甲苯洗涤。将固体溶于200mL饱和氯化铵和400mL的EtOAc中，并将水层用EtOAc萃取两次。合并有机层经硫酸镁干燥、过滤并蒸发，最终得到3-(2-吡嗪基)-3-氧代丙酸乙酯黄色固体，产率为6.52g，收率50％。

反应信息

• 作为反应物：
  描述：

  3-(2-吡嗪基)-3-氧代丙酸乙酯 在 diphosphorus pentasulfide 、 potassium carbonate 作用下， 以 丙酮 、 甲苯 为溶剂， 生成 吡噻硫酮
  参考文献：
  名称：

  1,2-Dithiole derivatives

  摘要：

  1,2-二硫代烯衍生物的结构式如下：##STR1## 其中Het代表一个芳香杂环基团，环中有六个原子，其中两个是氮原子，该杂环基团可以携带从卤素、烷基、烷氧基、巯基、烷硫基、二烷基氨基、吡咯烷-1-基、哌啶基、吗啉基和4-烷基哌嗪-1-基中选择的单个取代基，R代表卤素、烷基（可由烷氧羰基取代）、羧基、烷氧羰基、氨基甲酰基、N-烷基氨基甲酰基或一个R.sub.1--C(OH)--基团，其中R.sub.1代表氢或烷基，所述的烷基、烷氧基和烷硫基基团或含有1至4个碳原子的烷基或烷氧基基团，除了在R.sub.1是烷基时含有1至3个碳原子的情况下，这些化合物是治疗血吸虫病的新化合物。

  公开号：

  US04110450A1
• 作为产物：
  描述：

  2-甲酸吡嗪 、 丙二酸单乙酯 在 N,N'-羰基二咪唑 、 甲基溴化镁 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 2.0h， 以82%的产率得到3-(2-吡嗪基)-3-氧代丙酸乙酯
  参考文献：
  名称：

  Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

  摘要：

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

  DOI：

  10.1021/jm500462x

文献信息

• Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists
  申请人：Clasby C. Martin

  公开号：US20060135526A1

  公开（公告）日：2006-06-22

  Compounds having the structural formula I are disclosed, wherein A is alkylene, or optionally substituted arylene, cycloalkylene or heteroaryldiyl; X is —C(O)— or —S(O) 2 —; R 1 is alkyl or cycloalkyl; R 2 is hydrogen, halo or —CN; R 3 is hydrogen or alkyl; R 4 is hydrogen, alkyl, alkoxy, hydroxyalkyl, aminoalkyl-, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; or R 3 and R 4 , form an optionally substituted 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member; R 7 is alkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyl, halo, morpholinyl, optionally substituted piperazinyl, or optionally substituted azacycloalkyl. Also disclosed is the use of the compounds in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

  揭示了具有结构式I的化合物，其中A是烷基，或者可选择地取代的芳基，环烷基或杂芳基二基；X是—C(O)—或—S(O)2—；R1是烷基或环烷基；R2是氢，卤素或—CN；R3是氢或烷基；R4是氢，烷基，烷氧基，羟基烷基，氨基烷基，环烷基，杂环烷基，被烷基取代的杂环烷基，可选择地取代的芳基烷基或可选择地取代的杂芳基烷基；或者R3和R4形成一个可选择地取代的5-7成员环，所述环可选择地包含一个额外的杂原子环成员；R7是烷基，可选择地取代的苯基，可选择地取代的杂芳基，环烷基，卤素，吗啉基，可选择地取代的哌嗪基，或可选择地取代的氮杂环烷基。还揭示了这些化合物在帕金森病治疗中的用途，单独或与其他治疗帕金森病的药剂组合使用，包含它们的药物组合物和包含组合物组分的工具包。
• [EN] 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DE L'ACIDE 2-(PIPÉRIDINE-1-YL)-4-HÉTÉROCYCLYL-THIAZOLE-5-CARBOXYLIQUE UTILISÉS POUR LUTTER CONTRE LES INFECTIONS BACTÉRIENNES
  申请人：ASTRAZENECA AB

  公开号：WO2010067123A1

  公开（公告）日：2010-06-17

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. Ring A is selected from formula (a), (b) or (b'):

  化合物的结构式（I）及其药用盐已经描述。还描述了它们的制备方法、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。环A从式（a）、（b）或（b'）中选择。
• Beta-ketoester compounds
  申请人：Givaudan Roure (International) SA

  公开号：US06348618B1

  公开（公告）日：2002-02-19

  The beta-ketoesters of formula I are useful as precursors for organoleptic compounds, especially for flavors, fragrances and masking agents and antimicrobial compounds.

  公式I的β-酮酸酯可用作感官化合物的前体，特别是用于风味、香料、掩蔽剂和抗微生物化合物。
• Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents
  作者：Harvey I. Skulnick、Sheldon D. Weed、Emerson E. Eidson、Harold E. Renis、Dale A. Stringfellow、Wendell Wierenga

  DOI：10.1021/jm00150a018

  日期：1985.12

  2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone. An analogue study incorporating a series of 2-amino-5-substituted-6-arylpyrimidinones revealed that the most potent interferon inducers were mono- and difluorophenyl analogues. These same analogues were also potent antiviral agents against Semliki Forest virus and herpes simplex type 1. In addition the monomethoxyphenyl analogues were potent antiviral agents but weak interferon

  发现2-氨基-5-溴-6-苯基-4（3H）-嘧啶酮具有干扰素诱导作用和抗病毒活性。包含一系列2-氨基-5-取代-6-芳基嘧啶酮的类似物研究表明，最有效的干扰素诱导剂是单-和二氟苯基类似物。这些相同的类似物也是针对Semliki Forest病毒和1型单纯疱疹的有效抗病毒剂。此外，单甲氧基苯基类似物是有效的抗病毒剂，但是弱干扰素诱导剂。相对适度的结构变化导致生物活性发生巨大变化。循环干扰素水平与全身抗病毒活性之间的相关性相对较差。
• Structure–Activity Relationships of Pyrazolo[1,5-<i>a</i>]pyrimidin-7(4<i>H</i>)-ones as Antitubercular Agents
  作者：Sangmi Oh、M. Daben J. Libardo、Shaik Azeeza、Gary T. Pauly、Jose Santinni O. Roma、Andaleeb Sajid、Yoshitaka Tateishi、Caroline Duncombe、Michael Goodwin、Thomas R. Ioerger、Paul G. Wyatt、Peter C. Ray、David W. Gray、Helena I. M. Boshoff、Clifton E. Barry

  DOI：10.1021/acsinfecdis.0c00851

  日期：2021.2.12

  various modes of action against Mycobacterium tuberculosis (Mtb). We explored this scaffold through the synthesis of a focused library of analogues and identified key features of the pharmacophore while achieving substantial improvements in antitubercular activity. Our best hits had low cytotoxicity and showed promising activity against Mtb within macrophages. The mechanism of action of these compounds

  Pyrazolo[1,5 - a ]pyrimidin-7(4 H )-one 通过高通量全细胞筛选被鉴定为潜在的抗结核药物。该支架的核心之前已被多次鉴定，并且与抗结核分枝杆菌( Mtb ) 的各种作用模式有关。我们通过合成一个集中的类似物库探索了这种支架，并确定了药效团的关键特征，同时实现了抗结核活性的显着改善。我们的最佳产品具有低细胞毒性，并显示出对Mtb的有希望的活性巨噬细胞内。这些化合物的作用机制与细胞壁生物合成、异戊二烯生物合成或铁吸收无关，正如其他具有这种核心结构的化合物所发现的那样。黄素腺嘌呤二核苷酸 (FAD) 依赖性羟化酶 (Rv1751) 的突变赋予了对这些化合物的抗性，该羟化酶通过分子氧的羟基化促进化合物分解代谢。我们的结果强调了化学聚集的风险，但没有建立化学相关生长抑制剂的机制相似性。